Literature DB >> 6506136

Nonlinear metabolic disposition of theophylline.

R Dahlqvist, B Billing, J O Miners, D J Birkett.   

Abstract

Eleven healthy volunteers were given maintenance treatment with oral theophylline in increasing doses (210-1,260 mg/day). Seven subjects took four different doses, three subjects took three doses and one subject discontinued treatment after only two doses. Plasma and urine were collected during a dose interval at steady state. Theophylline in plasma and urine and metabolites in urine (1-methyluric acid, 1-MU; 3-methylxanthine, 3-MX; 1,3-dimethyluric acid, DMU) were determined by high-performance liquid chromatography. Total clearance of theophylline as well as clearances to all three metabolic products (but not theophylline renal clearance) decreased with increasing dose. The individual Michaelis-Menten parameters Km and Vmax could be estimated for six subjects who took all four doses. Considerable interindividual variability in these parameters and particularly Km:s was found. The Km for overall elimination averaged 133 mumol/L (range 55-213 mumol/L) and the Vmax 611 mumol/h (2,640 mg/day; range 452-813 mumol/h). With regard to individual metabolic routes, the Km for theophylline metabolism to 1-MU was 88 +/- 41 (mean +/- SD) mumol/L and the Vmax was 110 +/- 15 mumol/h; the Km for metabolism to 3-MX was 90 +/- 37 mumol/L and the Vmax was 78 +/- 13 mumol/h; the Km for metabolism to DMU was 179 +/- 92 mumol/L and the Vmax was 357 +/- 122 mumol/h. The Km values for the N-demethylation pathways (1-MU and 3-MX) were significantly correlated (r = 0.95; p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6506136     DOI: 10.1097/00007691-198409000-00006

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  12 in total

Review 1.  Adverse reactions and interactions with theophylline.

Authors:  M H Skinner
Journal:  Drug Saf       Date:  1990 Jul-Aug       Impact factor: 5.606

2.  Non-linear fluvoxamine disposition.

Authors:  O Spigset; K Granberg; S Hägg; E Söderström; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

3.  Plasma concentrations of theophylline and its metabolites in a theophylline intoxicated child--reevaluation of published Km-values.

Authors:  U Gundert-Remy; B Krüdewagen; R Hildebrandt
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

4.  Ciprofloxacin-induced theophylline toxicity: a population-based study.

Authors:  Tony Antoniou; Tara Gomes; Muhammad M Mamdani; David N Juurlink
Journal:  Eur J Clin Pharmacol       Date:  2011-01-14       Impact factor: 2.953

5.  Dose dependent pharmacokinetics of theophylline: Michaelis-Menten parameters for its major metabolic pathways.

Authors:  S Dadashzadeh; H Tajerzaden
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jan-Jun       Impact factor: 2.441

Review 6.  Theophylline. Pooled Michaelis-Menten parameters (Vmax and Km) and implications.

Authors:  J G Wagner
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

Review 7.  Theophylline poisoning. Pharmacological considerations and clinical management.

Authors:  P Gaudreault; J Guay
Journal:  Med Toxicol       Date:  1986 May-Jun

Review 8.  Review of Pharmacokinetic Data of Different Drug Classes in Goto-Kakizaki Rats, a Non-obese Model for Type 2 Diabetes Mellitus: Case Studies and Perspectives.

Authors:  Harilal Patel; Poonam Giri; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

Review 9.  Pharmacokinetic considerations in clinical toxicology: clinical applications.

Authors:  Darren M Roberts; Nick A Buckley
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Characterisation of theophylline metabolism in human liver microsomes.

Authors:  R A Robson; A P Matthews; J O Miners; M E McManus; U A Meyer; P M Hall; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.